Surgenex

Name

Surgenex

Legal name

Surgenex LLC

Website

https://surgenex.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Allograft Tissue Products

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836), Ophthalmic Goods (3851)

akta.pro primary industry

Acellular/Decellularized Matrices & ECM Products (HLAAAGAF)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)

Keywords

• Amniotic membrane allografts
• Placental tissue products
• Orthobiologic bone grafts
• Human tissue banking
• Wound care allografts

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

1. Allograft Tissue Products: Sale of human cellular and tissue-based products including placental-derived allografts (AmnioGraft, SurGraft series), chorion-derived products (ArdeoGraft series), bone matrix implants (SurMatrix DBM products), and structural/tendon allografts. Products sold with various HCPCS codes for reimbursement.
2. Contract Manufacturing & Research Services: Partnering with other organizations for distribution of Surgenex branded allografts, private label of established technology, technology transfer and custom processing, and full product and process development from concept to commercialization.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Surgenex manufactures and distributes human cellular and tissue-based allograft products, including dehydrated placental tissue allografts (ArdeoGraft, PelloGraft, RenoGraft, SanoGraft, VitoGraft, SurGraft family, SurSight), orthobiologic bone matrix implants (SurMatrix DBM putty, fibers, cancellous and cortical particulates, tendons, structural allografts), and acellular dermal matrix products. All allografts are processed using the proprietary Excellion® method at the company's Scottsdale, Arizona facility and sold to healthcare providers under HCPCS reimbursement codes.

Product overview

Surgenex is an industry leading biotechnology firm specializing in human cellular and tissue-based products, specifically placental tissue and musculoskeletal-based implants. The product portfolio consists of two main categories: Birth Tissue Allografts (placental-based products including ArdeoGraft, PelloGraft, RenoGraft, SanoGraft, VitoGraft, and the SurGraft family with variants like SurGraft AC, SurGraft ACA, SurGraft FT, SurGraft TL, and SurGraft XT, plus ocular product SurSight) and Orthobiologics/Bone Matrix products under the SurMatrix brand (including DBM Putty, Demineralized Cortical Fibers, DBM Cancellous products, Tendons, and Structural Allografts). The company also offers ArdeoGraft Surgical for surgical applications. All products are processed using the proprietary Excellion process under FDA cGTP and AATB standards.

Differentiator

Problem solved

Functional benefit

Products and services

• ArdeoGraft® Surgical Cutting-edge dual layer allograft derived from chorion, designed for both topical and surgical applications. Acts as a protective barrier offering exceptional coverage and shielding acute and chronic wounds from the surrounding environment. Intended for surgical applications.
• ArdeoGraft® Dual layer chorion-derived placental allograft designed for wound care applications. Provides a protective barrier and aids in the development of granulation tissue in acute and chronic closures.
• PelloGraft® Meticulously designed dual-layer amnion/chorion derived placental allograft. Properties of these avascular membranes provide enhanced handling. Effective as a protective covering in management of chronic non-healing ulcers including diabetic, pressure, and venous ulcers.
• RenoGraft® Triple-layer allograft comprised of amnion, chorion, and amnion layers. Meticulously designed for wound coverage using a proprietary manufacturing process, serving as a protective barrier to facilitate optimal wound care.
• SanoGraft® State-of-the-art single layer allograft derived from amnion. Serves as a protective barrier ensuring optimal protection for chronic non-healing ulcers including diabetic, pressure, and venous ulcers.
• VitoGraft®

Segments8 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Palomino GroupcoreStrategic or Co-development PartnerSurgenex partnered with the Palomino Group to launch a dedicated reimbursement hotline for customers. The partnership delivers expert reimbursement support including insurance benefit verification, prior authorization, appeal support, and billing/coding services. Hotline operates 8 a.m. – 8 p.m. EDT Monday-Friday with phone (1-888-404-9398), fax (1-888-404-9384), and email ([email protected]).
• Phoenix Donor ServicescoreOthersPhoenix Donor Services is referenced as the tissue procurement partner for Surgenex. Independent, contracted tissue recovery agencies follow strict protocols in accordance with FDA regulations and AATB standards.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Arthrex: Orthopedic and sports medicine device leader with allograft tendon, bone, and orthobiologic offerings that overlap directly with Surgenex's SurMatrix Tendons, structural allografts, and DBM products for foot & ankle and sports medicine applications.
• Smith+Nephew: Global medical device company with orthobiologics, wound care, and sports medicine franchises (including legacy Osiris Therapeutics placental tissue products). Competes with Surgenex in advanced wound management and orthobiologics through deep hospital sales coverage.
• Integra LifeSciences: Larger medical device incumbent with regenerative technology and DBM/orthobiologic lines (e.g., Integra Dermal Regeneration Template, Aurora DBM) competing with Surgenex's SurMatrix orthobiologics and dermal matrix products across hospital channels.
• Medtronic: Spinal surgery market leader with Infuse (rhBMP-2) and broader bone graft substitute portfolio. Competes against Surgenex's SurMatrix DBM and laminar bone products in spinal fusion procedures.
• Stryker: Diversified orthopedic medtech incumbent with bone graft substitute, regenerative, and sports medicine offerings. Competes with Surgenex's orthobiologic line in large hospital systems where Stryker holds orthopedic contracts.

Direct peers

• Organogenesis: Public regenerative medicine company with amniotic membrane products (e.g., Apligraf, Affinity, NuShield) overlapping Surgenex's placental allograft and wound care lines. Comparable customer base across wound care, surgical, and ophthalmic applications.
• AlloSource: Nonprofit tissue bank providing birth tissue, sports medicine, and orthobiologic allografts through AATB-accredited processing. Direct overlap with Surgenex's placental membrane and musculoskeletal product portfolios.
• MTF Biologics: Nonprofit tissue bank distributing placental, dermal, and musculoskeletal allografts with comparable AATB-accredited processing standards. Competes across the same wound care, orthobiologics, and surgical reconstruction segments.
• LifeNet Health: Nonprofit tissue bank and organ procurement organization offering placental, dermal, bone, and tendon allografts. Competes in the same wound care, dental, ophthalmic, and orthopedic reconstructive segments.
• MiMedx: Direct competitor in the placental tissue allograft space with branded EpiFix and AmnioFix amniotic membrane products for wound care and surgical applications. Comparable product positioning, reimbursement model, and target customer segments (wound care centers, ASCs, hospitals).

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/surgenex
• LinkedInlinkedin.com/company/surgenex
• Xx.com/surgenex

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Surgenex